BC Emergency Medical Assistant Licensing Canadian Free Trade Agreement (CFTA) Provincial Comparison

Application Requirements

Note: All out of province applicants applying to BC that have a lapse in practice will be assessed under the <u>Out of Province</u> <u>Assessment Policy</u> and examinations/training may be required in order to be eligible for BC licensure.

BC Jurisprudence Examination

All licensing candidates are required to successfully complete the jurisprudence examination. Candidates are required to complete the jurisprudence exam **every time** they apply for a new licence category. The online jurisprudence exam may be completed anywhere a candidate has internet access. Please ensure you review the <u>Applicant Guide to the B.C.</u> Jurisprudence Examination prior to attempting the exam.

Emergency Medical Responder

- <u>Alberta</u>
- Saskatchewan

- Manitoba
- Newfoundland and Labrador

Primary Care Paramedic

- Alberta
- <u>Saskatchewan</u>
- Manitoba
- Ontario
- Quebec

- New Brunswick
- Nova Scotia
- Newfoundland and Labrador
- Prince Edward Island

Advanced Care Paramedic

- Alberta
- Saskatchewan
- Manitoba
- Ontario

- New Brunswick
- Nova Scotia
- Newfoundland and Labrador
- Prince Edward Island

<u>Critical Care Paramedic</u>

- Saskatchewan
- Manitoba

• <u>Ontario</u>

Revised: November 19, 202 Page 1 of 16

Emergency Medical Responder (EMR)		
Province Of	Schedule 1 Restrictions	Schedule 2
Origin		Endorsements
Alberta	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (k) administration of epinephrine by intra-muscular auto-injector or intranasal or sublingual preparations (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) (o) intramuscular and intranasal administration of anti-hypoglycemic agents	(a) maintenance of intravenous lines (c) administration of the following oral, sublingual or inhaled medications: (i) anti-anginal (iii) analgesic (iv) platelet inhibitors (e) chest auscultation
Saskatchewan	EMA FR Services (g) nasopharyngeal airways (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (k) administration of epinephrine by intra-muscular auto-injector or intranasal or sublingual preparations (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) (o) intramuscular and intranasal administration of anti-hypoglycemic agents	(a) maintenance of intravenous lines (c) administration of the following oral, sublingual or inhaled medications: (i) anti-anginal (iii) analgesic (iv) platelet inhibitors (e) chest auscultation

	Emergency Medical Responder (EMR)		
Province Of	Schedule 1 Restrictions	Schedule 2	
Origin		Endorsements	
Newfoundland and Labrador	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (i) the patient has requested the EMA to assist the patient with the administration of the medication; (ii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iii) the medication is administered as prescribed, and (iv) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (k) administration of epinephrine by intra-muscular auto-injector or intranasal or sublingual preparations (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) (o) intramuscular and intranasal administration of anti-hypoglycemic agents EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (ii) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (iii) the patient has requested the EMA to assist the patient with the administration of the medication; (iv) the administration of the medication is related to the emergency services the EMA is providing to the patient; (v) the medication is administered as prescribed, and (vi) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (k) administration of epinephrine by intra-muscular auto-injector or intranasal or sublingual preparations (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) (o) intramuscular an	(c) administration of the following oral, sublingual or inhaled medications: (iv) platelet inhibitors	

	Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements	
Origin			
Alberta	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment	(b) administration of isotonic crystalloid solutions (d) electrocardiogram acquisition (e) initiation and maintenance of non-invasive positive pressure airway devices (f) administration of the following inhaled, intramuscular, intranasal, intraosseous, intravenous, nebulized, oral, subcutaneous or sublingual medications: (i) anti-emetic — anti-nauseant (ii) vitamins (iii) corticosteroids (iv) opioid analgesics (v) anti-cholinergic (i) taking microbiology swabs of dermal and mucosal sites (m) administration of chemical and biological agent countermeasures	

Revised: November 19, 202

	Primary Care Paramedic	
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Saskatchewan	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (ii) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	(b) administration of isotonic crystalloid solutions (d) electrocardiogram acquisition (e) initiation and maintenance of non-invasive positive pressure airway devices (f) administration of the following inhaled, intramuscular, intravenous, nebulized, oral, subcutaneous or sublingual medications: (i) anti-emetic — anti-nauseant

Revised: November 19, 202 Page **5** of **16**

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Manitoba	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (i) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (e) initiation of peripheral intravenous lines (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	n/a

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Ontario	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (ii) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (e) initiation of peripheral intravenous lines (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	(d) electrocardiogram acquisition (e) initiation and maintenance of non- invasive positive pressure airway devices (f) administration of the following inhaled, intramuscular, intravenous, nebulized, oral, subcutaneous or sublingual medications: (i) anti-emetic — anti-nauseant

Revised: November 19, 202 Page **7** of **16**

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Quebec	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (i) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (e) initiation of peripheral intravenous lines (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	n/a

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
New	EMA FR Services	n/a
Brunswick	(h) assistance to a patient with the administration of a	
DIGITSWICK	medication to the patient, provided that	
	(i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only	
	on the prescription of a health professional, the	
	medication has already been prescribed to the patient	
	by a health professional,	
	(ii) the patient has requested the EMA to assist the patient with the administration of the medication;	
	(iii) the administration of the medication is related to the	
	emergency services the EMA is providing to the patient;	
	(iv) the medication is administered as prescribed, and	
	(v) the patient is not being transported between health facilities	
	(i) use and interpretation of CO-oximeters	
	(I) topical administration of procoagulants and antifibrinolytics	
	(n) non-invasive blood pressure measurement (electronic	
	devices)	
	PCP Services	
	(b) administration of the following intraosseous and intranasal	
	medications:	
	(i) narcotic antagonist	
	(iii) anti-histaminic	
	(iv) sympathomimetic agent (v) procoagulant	
	(vi) anti-hypoglycemic agent	
	and (b) administration of the following intravenous,	
	intraosseous, oral, intranasal, sublingual, subcutaneous,	
	inhaled, intra-muscular or nebulized medications:	
	(vii) anti-pyretic	
	(e) initiation of peripheral intravenous lines	
	(f) point of care testing to inform emergency treatment or	
	transportation decisions or to provide information for	
	subsequent treatment (g) end-tidal carbon dioxide monitoring	
	[(g) enu-tiual carbon dioxide monitoring	

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Nova Scotia	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (i) narcotic antagonist (ii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	(b) administration of isotonic crystalloid solutions (f) administration of the following inhaled, intramuscular, intravenous, nebulized, oral, subcutaneous or sublingual medications: (i) anti-emetic — anti-nauseant (ii) vitamins

Revised: November 19, 202 Page **10** of **16**

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Newfoundland and Labrador	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (i) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, intraosseous, oral, intranasal, sublingual, subcutaneous, intraosseous, oral, intranasal, sublingual, subcutaneous, intraosseous, oral, intranasal, or nebulized medications: (vii) anti-pyretic (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	(b) administration of isotonic crystalloid solutions (f) administration of the following inhaled, intramuscular, intravenous, nebulized, oral, subcutaneous or sublingual medications: (ii) vitamins

Revised: November 19, 202 Page 11 of 16

Primary Care Paramedic		
Province Of	Schedule 1 Restrictions	Schedule 2 Endorsements
Origin		
Prince Edward Island	EMA FR Services (h) assistance to a patient with the administration of a medication to the patient, provided that (i) if, under the Pharmacy Operations and Drugs Scheduling Act, a particular medication is available only on the prescription of a health professional, the medication has already been prescribed to the patient by a health professional, (ii) the patient has requested the EMA to assist the patient with the administration of the medication; (iii) the administration of the medication is related to the emergency services the EMA is providing to the patient; (iv) the medication is administered as prescribed, and (v) the patient is not being transported between health facilities (i) use and interpretation of CO-oximeters (l) topical administration of procoagulants and antifibrinolytics (n) non-invasive blood pressure measurement (electronic devices) PCP Services (b) administration of the following intraosseous and intranasal medications: (ii) narcotic antagonist (iii) anti-histaminic (iv) sympathomimetic agent (v) procoagulant (vi) anti-hypoglycemic agent and (b) administration of the following intravenous, intraosseous, oral, intranasal, sublingual, subcutaneous, inhaled, intra-muscular or nebulized medications: (vii) anti-pyretic (f) point of care testing to inform emergency treatment or transportation decisions or to provide information for subsequent treatment (g) end-tidal carbon dioxide monitoring	(b) administration of isotonic crystalloid solutions (f) administration of the following inhaled, intramuscular, intravenous, nebulized, oral, subcutaneous or sublingual medications: (ii) vitamins

Revised: November 19, 202 Page **12** of **16**

Advanced Care Paramedic		
Province Of Origin	Schedule 1 Restrictions	Schedule 2 Endorsements
Alberta	n/a	(c) urinary catheterization
Saskatchewan	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) microbiology swabs (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise	(c) urinary catheterization
Manitoba	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) microbiology swabs (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise (o) administration of drug therapy after consultation with a medical practitioner who is designated by an employer as a medical oversight advisor and who has advised the EMA to administer the drug therapy	n/a
Ontario	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) microbiology swabs (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise	n/a
New Brunswick	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) microbiology swabs (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise (o) administration of drug therapy after consultation with a medical practitioner who is designated by an employer as a medical oversight advisor and who has advised the EMA to administer the drug therapy	n/a

Advanced Care Paramedic			
Province Of	Schedule 1 Restrictions	Schedule 2	
Origin		Endorsements	
Nova Scotia	EMA FR Services	n/a	
	(I) topical administration of procoagulants and antifibrinolytics		
	PCP Services		
	(i) microbiology swabs		
	(m) chemical and biological agent countermeasures		
	ACP Services		
	(n) reduction of joint dislocations involving neurological or vascular		
	compromise		
	(o) administration of drug therapy after consultation with a medical		
	practitioner who is designated by an employer as a medical oversight advisor		
	and who has advised the EMA to administer the drug therapy	1	
Newfoundland	EMA FR Services	n/a	
and Labrador	(I) topical administration of procoagulants and antifibrinolytics		
	PCP Services		
	(i) microbiology swabs		
	(m) chemical and biological agent countermeasures ACP Services		
	(n) reduction of joint dislocations involving neurological or vascular		
	compromise		
	(o) administration of drug therapy after consultation with a medical		
	practitioner who is designated by an employer as a medical oversight advisor		
	and who has advised the EMA to administer the drug therapy		
Prince Edward	EMA FR Services	n/a	
Island	(I) topical administration of procoagulants and antifibrinolytics		
ISIaIIU	PCP Services		
	(i) microbiology swabs		
	(m) chemical and biological agent countermeasures		
	ACP Services		
	(n) reduction of joint dislocations involving neurological or vascular		
	compromise		
	(o) administration of drug therapy after consultation with a medical		
	practitioner who is designated by an employer as a medical oversight advisor		
	and who has advised the EMA to administer the drug therapy		

Revised: November 19, 202 Page **14** of **16**

Critical Care Paramedic			
Province Of	Schedule 1 Restrictions	Schedule 2	
Origin		Endorsements	
Saskatchewan	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) taking microbiology swabs of dermal and mucosal sites (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise (n) invasive wound management (o) subcutaneous application of a local anesthetic (p) finger thoracostomy CCP Services (d) chest tube insertion (e) initiation of central venous line (f) escharotomy (g) esophageal manometry	n/a	
Manitoba	(h) pericardiocentesis EMA FR Services (l) topical administration of procoagulants and antifibrinolytics PCP Services (i) taking microbiology swabs of dermal and mucosal sites (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise (n) invasive wound management (o) subcutaneous application of a local anesthetic (p) finger thoracostomy CCP Services (d) chest tube insertion (e) initiation of central venous line (f) escharotomy (g) esophageal manometry (h) pericardiocentesis	n/a	

Critical Care Paramedic			
Province Of Origin	Schedule 1 Restrictions	Schedule 2 Endorsements	
Ontario	EMA FR Services (I) topical administration of procoagulants and antifibrinolytics PCP Services (i) taking microbiology swabs of dermal and mucosal sites (m) chemical and biological agent countermeasures ACP Services (n) reduction of joint dislocations involving neurological or vascular compromise (n) invasive wound management (o) subcutaneous application of a local anesthetic (p) finger thoracostomy CCP Services (d) chest tube insertion (e) initiation of central venous line (f) escharotomy (g) esophageal manometry (h) pericardiocentesis	n/a	

Revised: November 19, 202